Literature DB >> 24766688

Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.

Jason Chia-Hsien Cheng1, Jose G Bazan2, Jian-Kuen Wu3, Albert C Koong2, Daniel T Chang4.   

Abstract

PURPOSE: To identify various dosimetric parameters of bone marrow cavity that correlate with acute hematologic toxicity (HT) in patients with anal squamous cell carcinoma treated with definitive chemoradiation therapy (CRT). METHODS AND MATERIALS: We analyzed 32 patients receiving CRT. The whole pelvic bone marrow (PBM) and the lumbosacral spine (LSS) subregion were contoured for each patient. Marrow cavities were contoured using the Hounsfield units (HUs) of 100, 150, 200, and 250 as maximum density threshold levels. The volume of each region receiving at least 5, 10, 15, 20, 30, and 40 Gy was calculated. The endpoint was grade ≥3 HT (HT3+). Normal-tissue complication probability (NTCP) was evaluated with the Lyman-Kutcher-Burman (LKB) model. Maximal likelihood estimate was used to compare the parameter set. Logistic regression was used to test associations between HT and both dosimetric and clinical parameters.
RESULTS: Ten patients (31%) experienced HT3+. While dose to both LSS and PBM significantly predicted for HT3+, LSS was superior to PBM by logistic regression and LKB modeling. Constrained optimization of the LKB model for HT3+ yielded the parameters m = 0.21, n = 1, and TD50 = 32 Gy for LSS. The NTCP fits were better with the whole bone than with marrow cavity using any HU threshold. Mean LSS doses of 21 Gy and 23.5 Gy result in a 5% and 10% risk of HT3+, respectively. Mean dose and low-dose radiation parameters (V5, V10, V15, V20) of whole bone or bone cavities of LSS were correlated most significantly with HT3+.
CONCLUSIONS: For predicting the risk of HT3+, whole-bone contours were superior to marrow cavity and LSS was superior to PBM by LKB modeling. The results confirm PBM and LSS as parallel organs when predicting hematologic toxicity. Recommended dose constraints to the LSS are V10 ≤80%. An LSS mean dose of 23.5 Gy is associated with a 10% risk of HT.
Copyright © 2014 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24766688     DOI: 10.1016/j.prro.2013.07.011

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  15 in total

1.  Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.

Authors:  Jie Lee; Jhen-Bin Lin; Fang-Ju Sun; Kuo-Wei Lu; Chou-Hsien Lee; Yu-Jen Chen; Wen-Chien Huang; Hung-Chang Liu; Meng-Hao Wu
Journal:  Br J Radiol       Date:  2016-08-24       Impact factor: 3.039

2.  Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.

Authors:  Pierfrancesco Franco; Francesca Arcadipane; Riccardo Ragona; Adriana Lesca; Elena Gallio; Massimiliano Mistrangelo; Paola Cassoni; Vincenzo Arena; Sara Bustreo; Riccardo Faletti; Nadia Rondi; Mario Morino; Umberto Ricardi
Journal:  Med Oncol       Date:  2016-06-08       Impact factor: 3.064

3.  Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.

Authors:  Pierfrancesco Franco; Riccardo Ragona; Francesca Arcadipane; Massimiliano Mistrangelo; Paola Cassoni; Nadia Rondi; Mario Morino; Patrizia Racca; Umberto Ricardi
Journal:  Med Oncol       Date:  2016-11-04       Impact factor: 3.064

4.  Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.

Authors:  Diana A R Julie; Jung Hun Oh; Aditya P Apte; Joseph O Deasy; Ashlyn Tom; Abraham J Wu; Karyn A Goodman
Journal:  Acta Oncol       Date:  2015-05-18       Impact factor: 4.089

5.  Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.

Authors:  Talha Shaikh; Lora S Wang; Brian Egleston; Meher Burki; John P Hoffman; Steven J Cohen; Joshua E Meyer
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

6.  Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.

Authors:  P Franco; R Ragona; F Arcadipane; M Mistrangelo; P Cassoni; N Rondi; M Morino; P Racca; U Ricardi
Journal:  Clin Transl Oncol       Date:  2016-04-01       Impact factor: 3.405

7.  Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer.

Authors:  Samantha Warren; Christopher N Hurt; Thomas Crosby; Mike Partridge; Maria A Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-29       Impact factor: 7.038

8.  Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation.

Authors:  Pierfrancesco Franco; Christian Fiandra; Francesca Arcadipane; Elisabetta Trino; Francesca Romana Giglioli; Riccardo Ragona; Umberto Ricardi
Journal:  BMC Cancer       Date:  2017-11-02       Impact factor: 4.430

9.  Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial.

Authors:  Francesca Arcadipane; Patrick Silvetti; Francesco Olivero; Alessio Gastino; Roberta Carlevato; Ilaria Chiovatero; Lavinia Spinelli; Massimiliano Mistrangelo; Paola Cassoni; Giuliana Ritorto; Elena Gallio; Adriana Lesca; Riccardo Faletti; Francesca Romana Giglioli; Christian Fiandra; Umberto Ricardi; Pierfrancesco Franco
Journal:  J Pers Med       Date:  2021-05-18

10.  Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?

Authors:  Juefeng Wan; Kaitai Liu; Kaixuan Li; Guichao Li; Zhen Zhang
Journal:  Radiat Oncol       Date:  2015-08-04       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.